SSI Diagnostica Group, a global leader in clinical diagnostics for infectious gastric, respiratory and bloodborne diseases, is pleased to announce it has signed a refinancing agreement led by Bridgepoint Credit, one of Europe’s most experienced credit managers with over €14 billion of assets under management.

Nordea and Nykredit, two long-standing and trusted relationship banks, will also participate in the refinancing. The new facilities will refinance the existing debt in full and provide a foundation for M&A and other investments to grow the business and scale the organization.

Christina Lindved, CEO of SSI Diagnostica Group, comments:

“We are delighted to be partnering with Bridgepoint, Nordea, and Nykredit for the next stage of our growth plans. The partnership will allow us to further execute on our 5-year strategic plans and reach even more people in need of quality diagnostic solutions.”

Lars Henrik Vejrup Hansen, Chief Financial Officer of SSI Diagnostica Group, adds:

“The substantial investments in SSI Diagnostica Group are a strong validation of our business model, strategy and growth trajectory. The flexible structure of the financing allows us to operate strategically and invest in longer-term activities.”

The refinancing marks a significant milestone in the company’s growth journey towards reaching more people with quality diagnostic solutions with the aim of improving treatment outcomes globally.

SSI Diagnostica Group has been owned by Adelis Equity Partners since 2016, followed by a reinvestment in 2022 through a continuation vehicle alongside its LPs. The Group was advised on the refinancing by Lazard (financial advisor) and Kromann Reumert (legal advisor).